The high expression in the low-risk population may indicate that cancer cells in low-risk patients rely on the PD-1/PD-L1 signaling pathway to elude immune surveillance, whereas patients in the risk population who have PD-1 monoclonal antibodies may fare better (11). This evidence concerns the gene CD274 and cancer.